Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan-Feb;7(1-2 Suppl 1):S18-24.
doi: 10.5489/cuaj.275.

Optimal management of patients receiving cabazitaxel-based chemotherapy

Catherine Sperlich  1 , Fred Saad
Affiliations

Optimal management of patients receiving cabazitaxel-based chemotherapy

Catherine Sperlich et al. Can Urol Assoc J. 2013 Jan-Feb.

Abstract

The emergence of chemotherapy as a survival-improving treatment for metastatic castration-resistant prostate cancer has focused attention on the need for effective prevention and management of side effects. The most recent chemotherapeutic agent in this setting is cabazitaxel, licensed for use when the disease progresses on or after docetaxel-based treatment. Experience with cabazitaxel shows that, as with docetaxel, its side effects are largely predictable and manageable using methods that are already well-known to oncology teams. Patient education, clear instructions for when and how patients should seek advice, and properly implemented local policies on side effect management are essential to optimal patient care.

PubMed Disclaimer

References

    1. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12. - PubMed
    1. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54. - PubMed
    1. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005. - PMC - PubMed
    1. Asselah J, Sperlich C. Post-docetaxel options for further survival benefit in metastatic castration-resistant prostate cancer: questions of choice. Can Urol Assoc J. 2012;7:S11–S17. doi: 10.5489/cuaj.12285. 2013. - DOI - PMC - PubMed
    1. National Cancer Institute Surveillance, Epidemiology and End Results. SEER cancer statistics review 1975–2009. Available at: http://seer.cancer.gov. Accessed October 1, 2012.